Designing nanoscale drug delivery systems with tumor-targeting capability, controlled-release behavior, and responsiveness to the tumor microenvironment may be a good choice to efficiently utilize the biological function of KillerRed. The gene discussed is TNFRSF10B; the disease is neoplasm.